Arch Therapeutics Inc (ARTH) USD0.001

- Add to watchlist
- This stock can be held in a



Business summary
Arch Therapeutics, Inc. is a biotechnology company, which focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company's technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and also referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body.
Contact details
Important dates
General stock information
- Short code:
- ARTH
- ISIN:
- US03939W1099
- Market cap:
- $10.79 million
- Shares in issue:
- 237.07 million
- Sector:
- Health Care Supplies
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.